EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allurion Technologies's Enterprise Value is $31.24 Mil.
Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-50.91 Mil. Therefore, Allurion Technologies's EV-to-FCF for today is -0.61.
The historical rank and industry rank for Allurion Technologies's EV-to-FCF or its related term are showing as below:
ALUR'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.54 Med: -1.38 Max: -0.31
Current: -0.46
During the past 3 years, the highest EV-to-FCF of Allurion Technologies was -0.31. The lowest was -8.54. And the median was -1.38.
ALUR's EV-to-FCF is ranked worse than 100% of 382
companies
in the Medical Devices & Instruments industry
Industry Median: 27.355
vs ALUR: -0.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Allurion Technologies's EV-to-FCF
For the Medical Devices subindustry, Allurion Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allurion Technologies's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Allurion Technologies's EV-to-FCF falls into.
Allurion Technologies's current Enterprise Value is $31.24 Mil.
Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allurion Technologies's PE Ratio (TTM) for today is calculated as:
Allurion Technologies's share price for today is $3.58.
Allurion Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Allurion Technologies EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Allurion Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALUR has been successfully added to your 